With the approval of olaparib, how will your treatment of patients with pancreatic cancer change?
Listen to Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the role of testing for biomarkers and the current paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer.
In this downloadable PDF summary from a CCO podcast, Philip Philip, MD, PhD and Elena Chiorean, MD discuss the role of biomarker testing and PARP inhibitors in the treatment of pancreatic cancer.
In this video roundtable, watch 3 experts give their perspectives on the optimal management of patients with pancreatic cancer using PARP inhibitors, as well as emerging strategies with PARP inhibitors that they find promising.
Download this slideset on the current advances and evolving landscape of PARP inhibitors for patients with pancreatic cancer.